Impact of Comorbidity, Race, and Marital Status in Men Referred for Prostate Biopsy with PSA >20 ng/mL: A Pilot Study in High-Risk Patients

Table 1

Clinical and demographic data (). Values are reported as median (interquartile range) or number (%).

Age (years)	62.5 (57–73)
Race
AA	54 (69.2%)
Caucasian	24 (30.8%)
Marital Status
Married	44 (56.4%)
SDW	33 (43.6%)
BMI (kg/m^2)	27.5 (23.5–33.3)
CCI	3 (2–4)
PSA (ng/mL)	34.3 (24.2–55.4)
Prior PSA, yes	53 (67.9%)
Prior biopsy, yes	16 (20.5%)
Biopsy results, positive*	66 (84.6%)
Gleason score ()
6	5 (7.6%)
7	17 (25.8%)
8–10	44 (66.7%)
Clinical stage ()
T1c	33 (50%)
T2a	8 (12.1%)
T2b	11 (16.7%)
T2c	7 (10.6%)
T3a	5 (7.6%)
T3b	2 (3%)

AA: African-American, BMI: body mass index, CCI: Charlson Comorbidity Index, PSA: prostate-specific antigen, SDW: single, divorced, or widowed.
*One patient had two prior negative biopsies; one patient had one prior negative biopsy.